IL-18-BINDUNGSMOLEKÜLE

European patent · EP2892923 · In force

Register entry

Publication number
EP2892923
Application number
EP13792452
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Sep 5, 2013
Published
Jul 15, 2015
Granted
Mar 25, 2020
Protection ends at the latest
Sep 4, 2033
Next annual fee due
Sep 30, 2027
IPC classes
C07K 16/24 (2006.01)
A61K 39/395 (2006.01)
G01N 33/50 (2006.01)
Priority
US 201261697981 P 07.09.2012
PCT application
PCT/IB2013/058317 05.09.2013
PCT publication
WO2014/037899 13.03.2014
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Oct 1, 2026

    Next annual fee due on

    Next annual fee due on
    30.09.2026 → 30.09.2027

    Published in Swissreg on 01.10.2026

  2. Oct 1, 2025

    Next annual fee due on

    Next annual fee due on
    30.09.2025 → 30.09.2026

    Published in Swissreg on 01.10.2025

  3. Oct 3, 2024

    Change

    Published in Swissreg on 03.10.2024

  4. Oct 1, 2023

    Change

    Published in Swissreg on 01.10.2023

  5. Oct 1, 2022

    Change

    Published in Swissreg on 01.10.2022

  6. Mar 25, 2020

    Granted

    Published in Swissreg on 25.03.2020

Parties

Holder

Novartis AG

Lichtstrasse 35, 4056 Basel

Inventor

SCHLAEPPI, Jean-Marc Alfred

CH-4002 Basel

DIEFENBACH-STREIBER, Beate

82152 Planegg, DE

CAMPBELL, Emma Michelle

Horsham Sussex RH12 5AB, GB

KUNZ, Christian Carsten Silvester

82152 Planegg, DE

MARSHALL, Sylwia

Horsham Sussex RH12 5AB, GB

BARDROFF, Michael Otto

CH-4002 Basel

VAN HEEKE, Gino Anselmus

Horsham Sussex RH12 5AB, GB

BRANNETTI, Barbara

CH-4002 Basel

RONDEAU, Jean-Michel Rene

CH-4002 Basel

EBERTH, Adina

82152 Planegg, DE

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.